Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
7 hedge funds and large institutions have $145K invested in Timber Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 7 closing their positions.
3% less capital invested
Capital invested by funds: $149K → $145K (-$4.49K)
42% less funds holding
Funds holding: 12 → 7 (-5)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$9.35K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$17.3K |
| 2 |
VF
Virtu Financial
New York
|
-$12.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Barclays
London,
United Kingdom
| $52K | -$17.3K | -89 | -30% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $32K | – | – | – |
|
|
VF
3
Virtu Financial
New York
| $27K | -$12.1K | -62 | -37% |
|
|
4
Renaissance Technologies
New York
| $12K | +$9.35K | +48 | New |
|
5
Geode Capital Management
Boston,
Massachusetts
| $11K | – | – | – |
|
|
NFG
6
Norris Financial Group
Greenville,
South Carolina
| $5.51K | +$4.29K | +22 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $5K | +$2.73K | +14 | +280% |
|
8
Franklin Resources
San Mateo,
California
| – | -$2K | -7,292 | Closed |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$5K | -25 | Closed |
|
|
TSS
10
Two Sigma Securities
New York
| – | -$5K | -25 | Closed |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$5K | -23 | Closed |
|
12
Jane Street
New York
| – | -$4K | -22 | Closed |
|
|
LTFS
13
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$1K | -3 | Closed |
|
14
Victory Capital Management
San Antonio,
Texas
| – | -$1K | -3 | Closed |
|
TMBR Hedge Fund Activity: Q4 2019 in Review
7 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q4 2019, worth a combined $145K — down 3% from $149K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TMBR and 2 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $9.35K. The largest seller was Barclays, cutting an estimated $17.3K.
- 7 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q4 2019, down from 12 in Q3 2019.
- Funds reported $145K of Timber Pharmaceuticals, Inc. stock for Q4 2019, down 3% quarter-over-quarter.
- 2 funds opened new Timber Pharmaceuticals, Inc. positions in Q4 2019 and 7 closed out, a net change of -5 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q4 2019 was Renaissance Technologies, an estimated $9.35K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q4 2019 was Barclays, an estimated $17.3K sold.
Based on aggregated 13F filings for Q4 2019.